BioSpace News Archive

Oncternal Therapeutics, Inc. today announced the approval of an inducement award to one new employee, Anne C. Hansen, who is joining Oncternal as Senior Director, Clinical Data Management.

Alkeus Pharmaceuticals, Inc. today announced that new positive data from its TEASE-3 clinical trial of gildeuretinol in teenage and young-adult patients with early-stage Stargardt disease will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9 in Seattle.

Cassava Sciences, Inc. has been advised by NASDAQ that end-of-day tomorrow May 2, 2024, will be the last and final trading day for SAVAW warrants on NASDAQ.

Astellas Pharma Inc. and Poseida Therapeutics, Inc. today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, “Xyphos”) and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.

Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for central nervous system disorders, today announced the initiation of patient dosing with GM-1020 in a Phase 2a study in Major Depressive Disorder (MDD) to assess safety, tolerability, and efficacy.

The Melanoma Research Alliance, the world’s leading non-profit funder of melanoma research, announced its $12.6 million commitment to fund melanoma research supporting more than 30 scientists at leading academic and medical institutions in the United States and across the globe.

AbCellera, Viking Global Investors, and ArrowMark Partners announced that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies.

Bio-Rad Laboratories, Inc. today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).

GE HealthCare announced Revolution RT,i a new radiation therapy computed tomography solution with innovative hardware and software solutions to help increase imaging accuracy, while simplifying simulation workflow for a more personalized and seamless oncology care pathway experience for clinicians and patients.

Traverse Biotech, Inc. has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.